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Diagnosing COPD and supporting smoking cessation in general practice:
Evidenceepractice gaps
Abstract

Objectives: To review the accuracy of diagnoses of chronic obstructive pulmonary disease (COPD) in
primary care in Australia, and to describe smokers' experiences with and preferences for smoking cessation.
Design, setting and participants: Patients were invited to participate if they were at least 40 years old and had
visited participating general practice clinics in Melbourne at least twice during the previous 12 months,
reported being current or ex-smokers with a smoking history of at least 10 pack-years, or were being managed
for COPD. Interviews based on a structured questionnaire and case finding (FEV 1 /FEV 6 measurement)
were followed, when appropriate, by spirometry testing and assessment of health-related quality of life,
dyspnoea and symptoms. Results: 1050 patients attended baseline interviews (February 2015 - April 2017) at
41 practices. Of 245 participants managed for COPD, 130 (53.1%) met the spirometry-based definition
(post-bronchodilator FEV 1 /FVC < 0.7) or had a clinical correlation; in 37% of cases COPD was not
confirmed, and no definitive result was obtained for 9.8% of patients. Case finding and subsequent spirometry
testing identified 142 new COPD cases (17.6% of participants without prior diagnosis; 95% CI, 15.1-20.5%).
690 participants (65.7%) were current smokers, of whom 360 had attempted quitting during the previous 12
months; 286 (81.0%of those attempting to quit) reported difficulties during previous quit attempts. Nicotine
replacement therapy (205, 57.4%) and varenicline (110, 30.8%) were the most frequently employed
pharmacological treatments; side effects were common. Hypnotherapy was the most popular nonpharmacological option (62 smokers, 17%); e-cigarettes were tried by 38 (11%). 187 current smokers
(27.6%) would consider using e-cigarettes in future attempts to quit. Conclusions: COPD was both
misdiagnosed and missed. Case finding and effective use of spirometry testing could improve diagnosis. Side
effects of smoking cessation medications and difficulties during attempts to quit smoking are common. Health
professionals should emphasise evidence-based treatments, and closely monitor quitting difficulties and side
effects of cessation aids. Trial registration: Australian New Zealand Clinical Trials Registry
ACTRN12614001155684.
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Diagnosing COPD and supporting
smoking cessation in general practice:
evidenceepractice gaps
Jenifer Liang1, Michael J Abramson2, Nicholas A Zwar3,4, Grant M Russell5, Anne E Holland6,7,8, Billie Bonevski9,
Ajay Mahal2,10, Kirsten Phillips11, Paula Eustace12, Eldho Paul2,13, Sally Wilson1, Johnson George1
Abstract
The known Guidelines for the management of COPD
recommend spirometry testing when diagnosing COPD.
Smoking cessation reduces the risk of developing COPD and
slows lung function decline.

Objectives: To review the accuracy of diagnoses of chronic
obstructive pulmonary disease (COPD) in primary care in
Australia, and to describe smokers’ experiences with and
preferences for smoking cessation.

The new More than one-third of participants managed
for COPD did not meet the spirometric deﬁnition of the
disorder, while one in six participants not previously
diagnosed with COPD had spirometry test results consistent
with COPD.

Design, setting and participants: Patients were invited to
participate if they were at least 40 years old and had visited
participating general practice clinics in Melbourne at least twice
during the previous 12 months, reported being current or
ex-smokers with a smoking history of at least 10 pack-years, or
were being managed for COPD. Interviews based on a structured
questionnaire and case ﬁnding (FEV1/FEV6 measurement) were
followed, when appropriate, by spirometry testing and
assessment of health-related quality of life, dyspnoea and
symptoms.

The implications Case ﬁnding and effective use of spirometry
could improve the diagnosis of COPD in primary care. Health
professionals need to understand the smoking cessation
support preferences of smokers, offer evidence-based advice,
and closely monitor any difﬁculties or side effects during quit
attempts.

C

hronic obstructive pulmonary disease (COPD) is globally
a major public health problem that has signiﬁcant effects
on mortality, morbidity, and health resource utilisation; it
is the ﬁfth leading cause of death in Australia.1 The prevalence of
moderate to severe COPD is 7.5% among Australians aged 40
years or more, and 29.2% among those aged 75 years or more.2

COPD is characterised by airﬂow limitation. The Global
Initiative for Obstructive Lung Disease (GOLD)3 and the
national COPD-X guidelines4 each advocate using spirometry
for diagnosing COPD, but it is not undertaken in primary care
settings as frequently as recommended.5 This may contribute
to delaying diagnosis of COPD and the treatment of patients
at high risk.
Tobacco smoking is the most preventable risk factor for COPD.
Although the overall prevalence of smoking in Australia has
declined, 12% of people aged 14 years or more smoke daily.6 As
many as 50% of smokers develop clinically signiﬁcant COPD.7
Smoking cessation is the key to preventing and treating COPD.

Conclusions: COPD was both misdiagnosed and missed. Case
ﬁnding and effective use of spirometry testing could improve
diagnosis. Side effects of smoking cessation medications and
difﬁculties during attempts to quit smoking are common. Health
professionals should emphasise evidence-based treatments,
and closely monitor quitting difﬁculties and side effects of
cessation aids.
Trial registration: Australian New Zealand Clinical Trials
Registry ACTRN12614001155684.
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In this study, we reviewed the accuracy of COPD diagnoses in
primary care, and explored the quitting experiences and preferences of smokers attending general practice clinics.

j

including spirometry, can improve the diagnosis and management
of COPD in primary care.
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About one in ﬁve patients attending general practices is a smoker.8
Clinic visits provide good opportunities for general practitioners to
review respiratory symptoms and exposure to risk factors, to
suggest changes in smoking behaviour, and to provide advice
about cessation strategies, potentially reducing the risk of COPD.
Knowledge of the smoking experiences and cessation preferences
of smokers can inform individualised cessation interventions that
can be sustained by those attempting to quit. GPs are also well
placed to identify patients at higher risk of COPD.5 The optimal
application of case-ﬁnding approaches and diagnostic tools,

Results: 1050 patients attended baseline interviews (February
2015 e April 2017) at 41 practices. Of 245 participants
managed for COPD, 130 (53.1%) met the spirometry-based
deﬁnition (post-bronchodilator FEV1/FVC < 0.7) or had a
clinical correlation; in 37% of cases COPD was not conﬁrmed,
and no deﬁnitive result was obtained for 9.8% of patients.
Case ﬁnding and subsequent spirometry testing identiﬁed
142 new COPD cases (17.6% of participants without prior
diagnosis; 95% CI, 15.1e20.5%). 690 participants (65.7%)
were current smokers, of whom 360 had attempted quitting
during the previous 12 months; 286 (81.0% of those attempting
to quit) reported difﬁculties during previous quit attempts.
Nicotine replacement therapy (205, 57.4%) and varenicline
(110, 30.8%) were the most frequently employed
pharmacological treatments; side effects were common.
Hypnotherapy was the most popular non-pharmacological
option (62 smokers, 17%); e-cigarettes were tried by 38 (11%).
187 current smokers (27.6%) would consider using e-cigarettes
in future attempts to quit.

29

Research
Methods
The Review of Airway Dysfunction and Interdisciplinary
Community-based care in Adult Long-term Smokers
(RADICALS)9 study is an ongoing cluster randomised controlled
trial assessing an interdisciplinary model of care for reducing the
burden of COPD and smoking in Australian primary care. Baseline
data were obtained from participants enrolled between February
2015 and April 2017.
Recruitment of and data collection from clinics
and participants
The trial protocol has been reported elsewhere.9 Brieﬂy, 43 general
practice clinics in Melbourne were recruited with the assistance of
primary health networks and key informants, and by direct
recruitment. After obtaining signed agreement, clinics were
randomised to the control or intervention arms of the study. For the
purposes of this analysis, baseline data from the two groups have
been combined. Two clinics withdrew from the study before they
commenced recruiting participants.

MJA 208 (1)
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At each clinic, a research assistant searched the practice database
to identify eligible patients, and contacted them by mail or telephone to seek their participation. Patients were invited if they
were at least 40 years old and had visited a participating clinic at
least twice during the previous 12 months, reported being a
current or ex-smoker with a smoking history of at least 10 packyears, or were being managed for COPD. Patients who had a
documented diagnosis of COPD or were currently treated with
COPD-speciﬁc medications (muscarinic antagonists or longacting muscarinic antagonist/long-acting b-adrenergic agonist
combination therapies), were deemed to have a prior diagnosis
of COPD. Those with no history of smoking were also eligible if
they had spirometry-conﬁrmed COPD or were treated with
COPD-speciﬁc medications. After providing written informed
consent, eligible participants were interviewed at the practice
(one hour). Baseline demographic and clinical data were
collected, followed by case-ﬁnding procedures and referral for
spirometry, if indicated.10

30

Case ﬁnding, spirometry and COPD questionnaires
During the baseline interview, forced expiratory volume in
1 second/forced expiratory volume in 6 seconds (FEV1/FEV6) was
measured with the COPD-6 device (Vitalograph) according to
Lung Foundation Australia recommendations.10 Patients with an
FEV1/FEV6 value below 0.75, or who found COPD-6 testing
difﬁcult, were referred for spirometry testing and assessment of
health-related quality of life, dyspnoea, and symptoms with the St
George’s Respiratory Questionnaire (SGRQ),11 the modiﬁed
Medical Research Council (mMRC) dyspnoea scale,12 and the
COPD Assessment Test (CAT).13 If results from recent spirometry
testing undertaken outside the trial were available, they were also
assessed.
Pre- and post-bronchodilator spirometry testing was performed
with Easy on-PC spirometers (ndd Medizintechnik) by
trained research assistants in accordance with the American
Thoracic Society/European Respiratory Society guidelines.14
Post-bronchodilator spirometry testing was performed 10e15
minutes after 400 mg salbutamol was delivered by a metered dose
inhaler and spacer. Best efforts at forced expiration were selected
according to the spirometer algorithm. The COPD diagnosis was
deemed to be conﬁrmed if the post-bronchodilator FEV1/forced
vital capacity (FVC) ratio was less than 0.7. We devised an

algorithm with the assistance of respiratory scientists to guide
research assistants in determining whether spirometry test
results were consistent with COPD (online Appendix 1). If
results were ambiguous and required further interpretation, the
report was sent to a respiratory scientist or respiratory
physician. Patients were deﬁned as having a misdiagnosis if
they had been treated for COPD or had a documented
diagnosis of COPD, but did not meet the spirometric deﬁnition
of COPD.
Smoking
Data collected from smokers (regardless of whether they had
COPD) included smoking status (according to both self-report
and exhaled carbon monoxide testing), age at which they
started smoking, years of smoking, smoking-related behaviour,
pharmacological and non-pharmacological strategies tried
during attempts to quit in the preceding 12 months, side effects
of previous pharmacotherapy, and difﬁculties associated
with previous attempts to quit. The participants’ preferred
methods of smoking cessation for future attempts and their
motivation for and conﬁdence in giving up smoking were
also assessed.
Statistical analysis
Data were entered into an Access (Microsoft) database, and
analysed in Excel (Microsoft) and SPSS 24.0 (IBM). The characteristics of the recruited clinics and the baseline characteristics of
participants were summarised as means (with standard deviations
[SDs]), medians (with interquartile ranges [IQRs]), or numbers
(and percentages), depending on the type and distribution of data.
The characteristics (age, sex, country of birth, language spoken at
home, education, employment status, marital status, current living
arrangements, smoking status, spirometric conﬁrmation of COPD)
of those previously diagnosed with or treated for COPD were
compared with those of participants without a prior COPD diagnosis. Age, sex, current smoking status, SGRQ score, mMRC grade,
CAT score, FEV1/FVC ratio, and the severity of disease in incident
cases of COPD were also compared with those of participants with
a prior diagnosis of COPD. The statistical signiﬁcance of differences between groups was assessed in c2 or Fisher exact tests
(categorical variables), Student t tests (continuous variables) or
ManneWhitney U tests (ordinal variables). Conﬁdence intervals
(CIs) for proportions were estimated with the exact binomial
distribution. P < 0.05 (two-sided) was deemed statistically
signiﬁcant.
Ethics approval
This project was approved by the Monash University Human
Research Ethics Committee and the La Trobe University Human
Ethics Committee (reference, CF14/1018e2014000433).

Results
The characteristics of the recruited clinics are summarised in Box 1.
Spirometers were available in 16 of 43 practices. Many clinics had
had no staff trained in spirometry testing, smoking cessation, or
COPD management in the previous 2 years.
Of the 37 646 patients screened, 10 744 satisﬁed the inclusion
criteria; of these, 1050 (9.8%) attended baseline interviews at 41
clinics (Box 2; demographic and clinical characteristics: online
Appendix 2, table 1). Almost all participants underwent FEV1/

Research
2 Flow of participants through eligibility assessment,
COPD-6 testing, and spirometry testing

1 Characteristics of the 43 recruited clinics*
Characteristic
Type of practice
Single GP practice
Group GP practice/community health
centre/interdisciplinary practice
Number of GPs, median (IQR)
Number of patients on database,
median (IQR)
Spirometer available

6 (14%)
37 (86%)
5 (4e10)
8214 (2000e18 309)
16 (43%)

Staff training in the previous 2 years
Spirometry

13 (35%)

Smoking cessation

6 (17%)

COPD management

7 (20%)

COPD ¼ chronic obstructive pulmonary disease; IQR ¼ interquartile range. * Two
practices withdrew from the study after enrolment and before participant
recruitment. Some data are missing for all variables, except for practice type and
number of GPs. u

FEV6 testing during their baseline interview (1045, 99.5%); 272
(25.9% of all participants [95% CI, 23.3e28.7%] and 69.0% [95% CI,
64.2e73.6%] of those who underwent spirometry) had COPD
according to their spirometry test results.
Of the 245 participants with a prior COPD diagnosis, 91 (37%)
did not meet the spirometric deﬁnition of COPD or have a
clinical correlation (Box 3): 68 did not meet the criteria for
spirometry referral after COPD-6 testing, the spirometry results
for 14 were inconsistent with COPD after further interpretation
or clinical correlation, those for eight were within normal
limits, and the result for one participant was inconsistent
with the spirometry-based deﬁnition of COPD, but possibly
reﬂected a reversible obstructive disorder, such as asthma.
Further, 142 of 805 participants without a prior COPD diagnosis
(17.6%; 95% CI, 15.1e20.5%) had spirometry results consistent
with COPD (Box 3). The characteristics of 142 participants with
prior COPD diagnoses (prevalent cases) and 130 with new
diagnoses conﬁrmed by spirometry (incident cases) are
compared in Box 4.

j
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Current smokers would consider a variety of strategies in future
attempts to quit. Pharmacotherapy was the most popular (272,
39.9%); e-cigarettes would be considered by more than one-quarter
of smokers (187, 27.6%) (online Appendix 2, table 3).

More than one-third of participants with a prior diagnosis of
COPD did not meet the spirometric deﬁnition of the disorder,
while one in six participants not previously diagnosed with
COPD had spirometry test results consistent with COPD. The
mean age of patients with a prior diagnosis of COPD was
higher than for those without an existing COPD diagnosis; the
proportions of patients in this group with lower education
levels, without fulltime employment, without a partner, or
living alone were also larger than among participants without
an existing diagnosis (online Appendix 2, table 1). The mean
age for incident cases of COPD was lower and the disease
severity milder than for prevalent cases; lung function was
better in incident cases, and SGRQ and CAT scores were lower.
The proportion of patients with a prior diagnosis of COPD who
were current smokers (44%) was signiﬁcantly smaller than that
of those newly diagnosed on the basis of spirometry test results
(77%), and was also smaller than the proportion of all participants without a prior COPD diagnosis (72%), but still high. A
slight majority of current smokers had unsuccessfully attempted to quit during the previous year; difﬁculties during these
attempts were common. More than half of those attempting to
quit reported using nicotine replacements or varenicline; side

MJA 208 (1)

Of the 1050 participants who attended a baseline interview, 690
(65.7%) were current smokers, most of whom smoked
daily (646, 93.6% of smokers) (Box 5, Box 6). Of the current
smokers, 360 (52.2%) had attempted to quit at least once
during the previous 12 months. The pharmacological treatments
most frequently tried were nicotine replacement therapy
(205, 57.4%) and varenicline (110, 30.8%) (Box 7). Non-evidencebased treatments, including hypnotherapy (62, 17%) and
electronic cigarettes (38, 11%), were also frequently tried. Most
smokers (286, 81.0%) reported difﬁculties during past
attempts to quit, including urges to smoke (195, 55.2%) and
irritability or aggression (152, 43.1%) (online Appendix 2,
table 2). Of the 242 smokers who reported using cessation
medications, more than half (157, 68.9%) reported side effects
(data not shown).

Discussion
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3 Spirometric conﬁrmation of chronic obstructive pulmonary disease
(COPD) by spirometry test results or clinical correlation
All
participants

No prior
diagnosis
of COPD

Prior
diagnosis
of COPD

1050

805

245

Number referred
for spirometry

441 (42.0%)

264 (32.8%)

177 (72.2%)

Number who
underwent
spirometry

394 (37.5%)

234 (29.1%)

160 (65.3%)

COPD conﬁrmed

272 (25.9%)

142 (17.6%)

130 (53.1%)

COPD not
conﬁrmed

716 (68.2%)

625 (77.6%)

91 (37%)

No result*

62 (5.9%)

38 (4.7%)

24 (9.8%)

Number of
participants

P

< 0.001

but diagnostic spirometry is not employed appropriately. In an earlier study in Australian primary care,
only 58% of patients receiving treatment for COPD
met the spirometric criteria for the disorder.16 Lack of
access to a spirometer, inadequate training in performing spirometry and interpreting the results, and
poor remuneration are among the many challenges
for lung function testing in primary care.16,17 Lack of
awareness of the need for spirometry testing for
diagnosing COPD may lead to diagnoses based on
social history, symptoms, or chest x-rays alone.
Misdiagnosis can lead to unnecessary or inappropriate treatment, potentially with adverse consequences. Underdiagnosis delays initiation of lifestyle
changes and targeted therapy, leading to an increased
risk of exacerbations and pneumonia.18

The approach to diagnosing COPD in Australia is
reactive; formal diagnosis follows the initial presentation of symptoms by patients, and there is inadequate
emphasis on case ﬁnding in smokers.19 Our case-ﬁnding
approach — FEV1/FEV6 testing of high risk patients
followed by spirometry testing and symptom questionnaires —
identiﬁed 142 new cases of COPD that may not have been recognised until symptoms developed as the disease progressed.

* It was not possible to obtain interpretable results from 62 participants referred for spirometry
testing (uncontactable or declined spirometry, 47; inconclusive results, 15). u

effects were frequent. Interest in non-evidence-based smoking
cessation strategies was high.
Our study highlights the importance of applying evidencebased guidelines to COPD management and smoking cessation support in Australian primary care. COPD diagnosis and
management guidelines are widely disseminated in Australia,15

Recommendations about screening for early identiﬁcation of
COPD are inconsistent. The United States Preventive Service Task
Force (USPSTF) found no overall beneﬁt in spirometry-based
screening of asymptomatic individuals.20 However,
the National Institute for Health and Care Excellence
(NICE) guidelines recommend opportunistic case
4 Characteristics of participants with prior and new diagnoses of
ﬁnding based on risk factors such as age, smoking, and
chronic obstructive pulmonary disease (COPD) conﬁrmed by
symptoms.21 Lung Foundation Australia recommends
spirometry testing
using symptom questionnaires to assist with COPD case
Incident cases
Prevalent cases
ﬁnding and diagnosis, especially in conjunction with
(no prior
(prior COPD
FEV1/FEV6 assessment, for which an upper threshold of
Characteristic
COPD diagnosis)
diagnosis)
P
0.75 is highly sensitive and speciﬁc.22 All case-ﬁnding
Number of participants
142
130
approaches increase the detection of COPD in primary
Age (years), mean (SD)
62.0 (10.7)
67.4 (10.2)
< 0.001
care, although the effects on clinical care and patient
outcomes need to be further investigated.23
Sex (men)
89 (63%)
78 (60%)
0.65
Currently smoking

109 (77%)

57 (44%)

< 0.001

SGRQ score,* mean (SD)

26.3 (16.5)

38.6 (17.7)

< 0.001

mMRC grade,† median (IQR)
CAT score,‡ mean (SD)
Post-bronchodilator
FEV1/FVC ratio,
median (IQR)§

1 (0e1)

1 (1e2)

< 0.001

11.3 (7.0)

15.3 (7.9)

< 0.001

0.62 (0.56e0.67)

0.56 (0.46e0.62)

< 0.001

117 (83.6%)

73 (57%)

16 (11%)

40 (31%)

7 (5%)

16 (12%)

Severity of disease§,{

MJA 208 (1)
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Mild
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Moderate
Severe

< 0.001

FEV1/FVC ¼ forced expiratory volume in 1 second/forced vital capacity ratio; IQR ¼ interquartile
range; SD ¼ standard deviation. * St George’s Respiratory Questionnaire: 50-item questionnaire
for assessing health status in patients with diseases of airway obstruction; range, 0e100; higher
scores indicate lower health-related quality of life. Data missing for 14 participants (six incident,
eight prevalent cases). † Modiﬁed Medical Research Council dyspnoea scale: scale consisting of
ﬁve statements; range, 0 (no dyspnoea) to 4 (very severe dyspnoea). Data missing for one
incident case. ‡ COPD Assessment Test: eight-item questionnaire for assessing health status of
patients with COPD; range, 0e40; higher scores indicate poorer health. Data missing for one
incident case. x Data missing for three participants (one prevalent and two incident cases)
because only pre-bronchodilator spirometry was performed. { Severity of COPD based on
FEV1% predicted values (mild, 60e80% predicted; moderate, 40e59% predicted;
severe, < 40% predicted).4 Eighty participants had FEV1% predicted values of more than 80, but
had characteristic symptoms of mild COPD. u

The reported rates of pharmacological and
non-pharmacological agent use in our study were
similar to those found by an earlier study of smoking
cessation aids used by smokers admitted to three
Victorian hospitals,24 in which nicotine replacement
therapy was also the most frequently used pharmacotherapy and hypnotherapy the most common
non-pharmacological therapy. Combination nicotine
replacement therapy and varenicline are the most
effective quitting aids, and are of similar efﬁcacy.25
In our study, only one-third of current smokers
reported trying varenicline, despite strong evidence
for its effectiveness.25 Further, it is reported that
few smokers continue pharmacotherapy for the recommended duration of treatment.24
Nicotine replacement therapy is widely available
from pharmacies and supermarkets, while varenicline
is a prescription-only drug, requiring a visit to a GP
and Pharmaceutical Beneﬁts Scheme authority
approval. Many of our participants reported interest
in using medications in future attempts to quit, but
more than one-quarter would also consider going
“cold turkey”. As the success rate of unassisted

Research
5 Characteristics of the 1050 participants who completed the baseline
interview

Characteristic

Total
participants

No prior
diagnosis
of COPD

Prior
diagnosis
of COPD

P

participants was objectively conﬁrmed by exhaled
carbon monoxide testing when possible. However,
we also relied upon participant reports, which are
subject to recall bias. Response and social desirability
bias may have also inﬂuenced survey responses.

As with other general practice studies of smokers and
COPD populations, the participation rate was modest
(10%), possibly affecting our estimates of prevalence
Age (years), mean
60.5 (11.1)
58.5 (10.4)
67.1 (10.6) < 0.001
and incidence rates and the generalisability of our
(SD)
results. However, the characteristics of our particiSex (men)
564 (53.7%)
433 (53.8%)
131 (53.5%)
0.93
pants were similar to those of a group recruited for a
Born in Australia*
735 (70.3%)
571 (71.2%)
164 (67.5%)
0.27
comparable study across 44 general practices in
Current smokers
690 (65.7%)
582 (72.3%)
108 (44.0%) < 0.001
Sydney that found similar rates of COPD misdiagnosis.16 Patients who volunteered for the trial may
Daily smokers
646 (61.5%)
542 (67.3%)
104 (42.4%) < 0.001
have been more motivated than those who did not,
Occasional smokers
44 (4.2%)
40 (5.0%)
4 (1.6%)
0.022
and may therefore not be representative of all eligible
Ex-smokers
350 (33.3%)
222 (27.6%)
128 (52.2%) < 0.001
patients. We could not verify the self-reported use of
Never smokers
10 (1.0%)
1 (0.1%)
9 (3.7%)
< 0.001
smoking cessation aids in medical records or
dispensing and prescribing data, but the research
COPD ¼ chronic obstructive pulmonary disease; SD ¼ standard deviation. * Data missing for ﬁve
participants. Additional demographic data is included in online Appendix 2, table 1. u
assistants responsible for collecting information were
practising pharmacists familiar with smoking cessation medications and in taking medication histories.
cessation is low, it should be recommended to all smokers Some patients used their COPD medications on the day of
interested in quitting that they seek assistive pharmacotherapy, spirometry testing, possibly causing detection errors.
together with counselling and support, unless there are contraindications.26 Consultations with smokers in general practice
provide opportunities for counselling and motivational support, Conclusions and implications for practice
crucial to successful quitting. The Royal Australian College of Evidence-based guidelines for the optimal diagnosis and
General Practitioners (RACGP) guidelines (speciﬁcally, the 5As management of COPD must be actively promoted and implestructure: ask, assess, advise, assist, and arrange follow-up) mented in Australian primary care. GPs and other primary care
practitioners should be educated about the role of spirometry
should guide smoking cessation support.26
testing in COPD diagnosis, and provided with resources and inSmokers frequently try non-evidence-based methods for centives for adopting it in practice. Early identiﬁcation of potential
quitting. Although hypnotherapy was popular with our COPD in individuals at high risk by case ﬁnding may facilitate
participants, evidence for its efﬁcacy is scant.27 The degree to earlier diagnosis and initiation of treatment.
which participants have used e-cigarettes as cessation aids and
the relatively high interest in trialling them in future attempts is In accordance with RACGP guidelines, smoking cessation
worrying. The efﬁcacy of e-cigarettes as a smoking cessation aid strategies of proven effectiveness should be recommended to
and their long term safety are unknown.28 Despite widespread all smokers. Patients may ask health professionals about the
popularity in some countries, e-cigarettes are not approved by efﬁcacy and safety of non-evidence-based methods, including
the Therapeutic Goods Administration, nor are they recom- e-cigarettes, hypnotherapy and acupuncture; e-cigarettes, in
mended by the National Health and Medical Research Council particular, should not be recommended. Past experience
as a cessation aid.29
Number of
participants

1050

805

245

We recruited a large sample of participants from a diverse range
of practices across Melbourne (including specialised clinics
serving people from lower socio-demographic status areas, and
drug and alcohol addiction clinics). The smoking status of

7 Self-reported pharmacological and non-pharmacological
treatments by 360 current smokers who had attempted to
quit at least once in the previous year
Treatment*
Evidence-based treatments

Characteristic
37.2 (11.0)

Exhaled carbon monoxide level* (ppm), median (IQR)

21 (13e28)
6 (4e8)

Conﬁdence in giving up smoking, median (IQR)‡

5 (3e7)

IQR ¼ interquartile range; SD ¼ standard deviation. * Exhaled carbon monoxide level
below 7 ppm conﬁrms participant is a non-smoker (manufacturer’s recommended
cut-off). Carbon monoxide breath tests could not be obtained from six participants;
46 current smokers (self-report) had levels below threshold, 21 non-smokers (selfreport) had levels at or above threshold. † Scale, 1 (low) to 10 (high); data missing
for six participants. ‡ Scale, 1 (low) to 10 (high); data missing for seven
participants. u

110 (30.8%)

Quitline

29 (8%)

Bupropion

25 (7%)

Non-evidence-based treatments
Hypnotherapy

62 (17%)

E-cigarettes

38 (11%)

Acupuncture
Other†

21 (6%)
41 (12%)

* Multiple selections possible; missing data for three participants. † For example,
cold turkey, herbal cigarettes, homeopathic remedies, DVDs or books, counselling,
Quit smoking group, online program. u
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Motivation to give up smoking, median (IQR)†

205 (57.4%)

Varenicline

j

Number of years of smoking, mean (SD)

Nicotine replacement therapy

MJA 208 (1)

6 Characteristics of the 690 participants who were current
smokers
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Research
with attempts to quit, reasons for relapse, and preferences
for future smoking cessation attempts should inform recommendations about cessation and assessment of the need for
monitoring.
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